Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Xeris Pharmaceuticals Inc (NQ: XERS )

4.460 USD -0.480 (-9.72%)
Streaming Delayed Price Updated: 11:00 AM EST, Mar 5, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All news about Xeris Pharmaceuticals Inc

< Previous 1 2 3 4 5 6 7 8 9 Next >
66 Biggest Movers From Yesterday
Gainers Net Element, Inc. (NASDAQ: NETE) shares surged 61.2% to close at $5.32 on Thursday after the company disclosed that its ... 
Tags CETX SES KEYS
From Benzinga
48 Stocks Moving In Thursday's Mid-Day Session
Gainers Net Element, Inc. (NASDAQ: NETE) shares climbed 27% to $4.19 after the company disclosed that its subsidiary, Unified ... 
Tags DPW HMLP XERS
From Benzinga
110 Biggest Movers From Yesterday
Gainers Corindus Vascular Robotics, Inc. (NYSE: CVRS) climbed 76.5% to close at $4.27 on Thursday after the company agreed to be ... 
Tags Movers AUTO DBVT
From Benzinga
Xeris Pharmaceuticals Announces Second Quarter 2019 Financial Results and Highlights
From GlobeNewswire News Releases
Xeris Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From GlobeNewswire News Releases
Commit To Buy Xeris Pharmaceuticals At $10, Earn 40.2% Annualized Using Options
Investors eyeing a purchase of Xeris Pharmaceuticals Inc (XERS) stock, but tentative about paying the going market price of $11.64/share, might benefit from considering selling puts among the... 
Tags Stocks
From Market News Video
Xeris Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug... 
From GlobeNewswire News Releases
Xeris Pharmaceuticals Doses First Patient in Phase 2 Trial Evaluating Its Developmental Ready-to-use Glucagon in Patients at Risk From Hypoglycemia Following Bariatric Surgery
Xeris has dosed the first subject in a Phase 2 trial with its developmental ready-to-use glucagon in patients with PBH. 
From Business Wire News Releases
Analysts Anticipate 10% Gains Ahead For IWV
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and... 
Tags ETFs
From ETF Channel
Xeris Pharmaceuticals Announces Additional Positive Outcomes from a Global Phase 3 Clinical Trial of Its Investigational Ready-to-Use Glucagon
Xeris announced positive findings from a global Phase 3 trial of its ready-to-use (RTU) room-temperature stable liquid glucagon conducted in Europe. 
From Business Wire News Releases
50 Biggest Movers From Yesterday
Gainers CrowdStrike Holdings, Inc. (NASDAQ: CRWD) shares jumped 70.6% to close at $58.00 on Wednesday after pricing its IPO at $34 ... 
Tags HEB Leisure Products JMIA
From Benzinga
The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Readouts
Biotech stocks staged a steady recovery last week. ASCO presentations dominated the headlines, with Iovance Biotherapeutics Inc (NASDAQ: ... 
Tags XBI FTSV INCY
From Benzinga
The Daily Biotech Pulse: Vertex Bets Big On Gene-Editing Therapies, Sanofi Poaches Novartis For CEO Role, Relief In Europe for Endologix
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting ... 
Tags CRSP SBPH XERS
From Benzinga
55 Biggest Movers From Yesterday
Gainers La Jolla Pharmaceutical Company (NASDAQ: LJPC) jumped 92.48 percent to close at $10.24 on Thursday after the company's ... 
Tags RIOT Movers From Yesterday LBY
From Benzinga
Xeris Pharmaceuticals Receives Notification of PDUFA Date Extension for Gvoke™
Conference call and webcast today at 5:00 pm ET 
From GlobeNewswire News Releases
42 Stocks Moving In Thursday's Mid-Day Session
Gainers ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV) shares jumped 133 percent to $11.65 after the company showed results from ... 
Tags SAIC GRVY VRA
From Benzinga
66 Biggest Movers From Yesterday
Gainers ReWalk Robotics Ltd. (NASDAQ: RWLK) shares jumped 122.9 percent to close at $7.40 on Wednesday following news the FDA ... 
Tags Pre/Market Outlook ANFI RAD
From Benzinga
Xeris Pharmaceuticals Announces First Quarter 2019 Financial Results and Highlights Its Pipeline
Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible... 
From GlobeNewswire News Releases
Xeris Pharmaceuticals Announces Results From a Phase 1 Study of Its Novel Formulation of Diazepam
Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug... 
From GlobeNewswire News Releases
Xeris Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug... 
From GlobeNewswire News Releases
Xeris Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug... 
From GlobeNewswire News Releases
Xeris Pharmaceuticals Presents New Clinical and Economic Impact Data on Its Developmental Ready-to-Use Glucagon
Xeris is presenting data on its developmental ready-to-use (RTU) room-temperature stable liquid glucagon at two medical conferences. 
From Business Wire News Releases
Xeris Pharmaceuticals Doses First Patient in Phase 2 Trial Evaluating Its Ready-to-Use Glucagon to Address Exercise-Induced Hypoglycemia
Xeris has initiated a trial with its ready-to-use, liquid-stable glucagon in Type 1 diabetes patients who experience exercise-induced hypoglycemia. 
From Business Wire News Releases
Wednesday 3/13 Insider Buying Report: XERS, ATEC
As the saying goes, there are many possible reasons for an insider to sell a stock, but only one reason to buy they expect to make money. So let's look at two noteworthy recent insider buys. 
Tags Stocks
From Market News Video
Implied IWO Analyst Target Price: $233
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and... 
Tags ETFs
From ETF Channel
Xeris Pharmaceuticals Enters Oversold Territory (XERS)
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a... 
Tags Stocks
From Market News Video
Xeris Pharmaceuticals Announces Fourth Quarter and Full Year 2018 Financial Results and Highlights Pipeline Progress
Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug... 
From GlobeNewswire News Releases
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug... 
From GlobeNewswire News Releases
Xeris Pharmaceuticals to Participate at SVB Leerink Global Healthcare Conference
Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug... 
From GlobeNewswire News Releases
The Daily Biotech Pulse: Acorda Swings To Profit, Achaogen Offering, Bioblast Strikes Sanfilippo Syndrome Deal
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting ... 
Tags IBB MNOV IMMU
From Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.